CN111505281A - A sensitizing immunochromatographic kit for sensitive detection of novel coronavirus antibodies - Google Patents
A sensitizing immunochromatographic kit for sensitive detection of novel coronavirus antibodies Download PDFInfo
- Publication number
- CN111505281A CN111505281A CN202010310112.2A CN202010310112A CN111505281A CN 111505281 A CN111505281 A CN 111505281A CN 202010310112 A CN202010310112 A CN 202010310112A CN 111505281 A CN111505281 A CN 111505281A
- Authority
- CN
- China
- Prior art keywords
- solution
- colloidal gold
- copper
- copper growth
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 19
- 238000011896 sensitive detection Methods 0.000 title description 7
- 230000001235 sensitizing effect Effects 0.000 title description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 94
- 238000012360 testing method Methods 0.000 claims abstract description 65
- 238000001514 detection method Methods 0.000 claims abstract description 62
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229910052802 copper Inorganic materials 0.000 claims abstract description 49
- 239000010949 copper Substances 0.000 claims abstract description 49
- 239000000523 sample Substances 0.000 claims abstract description 23
- 239000012528 membrane Substances 0.000 claims abstract description 19
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 17
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 17
- 230000035945 sensitivity Effects 0.000 claims abstract description 16
- 239000002250 absorbent Substances 0.000 claims abstract description 7
- 230000002745 absorbent Effects 0.000 claims abstract description 7
- 230000003287 optical effect Effects 0.000 claims abstract description 6
- 229920003023 plastic Polymers 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 64
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 11
- 238000003908 quality control method Methods 0.000 claims description 11
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 10
- 239000012498 ultrapure water Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 8
- 229920002873 Polyethylenimine Polymers 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 229910001431 copper ion Inorganic materials 0.000 claims description 8
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 8
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 8
- 229960005055 sodium ascorbate Drugs 0.000 claims description 8
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 239000008055 phosphate buffer solution Substances 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 7
- 229940038773 trisodium citrate Drugs 0.000 claims description 7
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 5
- 239000003365 glass fiber Substances 0.000 claims description 5
- 238000003317 immunochromatography Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 206010070834 Sensitisation Diseases 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 230000008313 sensitization Effects 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000002078 nanoshell Substances 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 239000012488 sample solution Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001601 polyetherimide Polymers 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims 6
- 238000002156 mixing Methods 0.000 claims 2
- 238000005303 weighing Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 14
- 238000011841 epidemiological investigation Methods 0.000 abstract 1
- 230000003321 amplification Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 229910052737 gold Inorganic materials 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- -1 silver ions Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及免疫层析分析技术领域,具体涉及一种灵敏检新型冠状病毒抗体的增敏型免疫层析试剂盒,其技术原理为双抗原夹心法。The invention relates to the technical field of immunochromatographic analysis, in particular to a sensitized immunochromatographic kit for sensitive detection of novel coronavirus antibodies, the technical principle of which is a double-antigen sandwich method.
背景技术Background technique
胶体金免疫层析试纸条因其简单、快速、方便以及裸眼检测已被广泛应用于临床诊断、食品安全检测以及环境监控等领域。传统胶体金免疫层析试纸条主要采用粒径为20~40nm胶体金作为信号探针,然而由于其较小的粒径导致其比色信号强度相对偏弱,进而导致其检测灵敏度偏低。相对较低的检测灵敏度在一定程度上局限了其在超灵敏检测中的应用。近些年,随着纳米科学和技术的快速发展,各种各样的新型纳米材料如荧光微球、量子点、量子点微球、上转换荧光纳米粒子、碳纳米材料以及磁性材料已经被报道可用于替代胶体金作为检测探针提高传统免疫层析试纸条的检测灵敏度,但这些纳米探针的合成相对复杂,价格昂贵很难被市场推广使用。相对于这些新型纳米材料,胶体金因其合成简单、易修饰、生物相容性好、光学性质稳定以及易读取等优势一直以来在免疫层析试纸条占据主要的位置,特别是在商业化生产中,其市场占有率达90%以上。因此,如何提高传统胶体金免疫层析试纸条的检测灵敏度对于进一步拓展其在超灵敏检测中的应用具有重要意义。Colloidal gold immunochromatographic test strips have been widely used in clinical diagnosis, food safety testing and environmental monitoring due to their simplicity, rapidity, convenience and naked eye detection. Traditional colloidal gold immunochromatographic test strips mainly use colloidal gold with a particle size of 20-40 nm as a signal probe. However, due to its small particle size, its colorimetric signal intensity is relatively weak, resulting in a low detection sensitivity. The relatively low detection sensitivity limits its application in ultrasensitive detection to a certain extent. In recent years, with the rapid development of nanoscience and technology, various new nanomaterials such as fluorescent microspheres, quantum dots, quantum dot microspheres, upconversion fluorescent nanoparticles, carbon nanomaterials, and magnetic materials have been reported. It can be used to replace colloidal gold as a detection probe to improve the detection sensitivity of traditional immunochromatographic test strips, but the synthesis of these nanoprobes is relatively complex, expensive and difficult to be used in the market. Compared with these new nanomaterials, colloidal gold has always occupied a major position in immunochromatographic test strips due to its advantages of simple synthesis, easy modification, good biocompatibility, stable optical properties and easy reading, especially in commercial applications. In chemical production, its market share is over 90%. Therefore, how to improve the detection sensitivity of traditional colloidal gold immunochromatographic test strips is of great significance to further expand its application in ultrasensitive detection.
基于试纸条检测线信号放大策略因无需合成额外的辅助信号放大材料,因而得到了科研工作者的广泛关注。该类策略主要包括以下几类:1)双金信号放大技术:在传统胶体金免疫层析试纸条的基础上,通过引入信号扩增金标垫,其可以借助抗原抗体反应和生物素-链霉亲和素系统等特异性地在检测线结合金标抗体偶联物,导致胶体金纳米粒子的进一步聚集,从而放大胶体金的比色信号,如专利CN102507929A;2)酶增强技术:在传统胶体金免疫层析试纸条的基础上,通过引入辣根过氧化物酶或具有过氧化物酶活性的纳米酶催化氧化相应的底物如四甲基联苯胺(TMB)等生成有色的沉淀物沉积于检测线,从而使胶体金的比色信号得到放大;3)金或银染增强技术:在传统胶体金免疫层析试纸条的基础上,当还原剂存在的情况下,金或银离子容易以胶体金为核心,聚集在胶体金表面还原成金或银原子,使纳米级大小的胶体金通过金或银离子的聚集和还原生长为更大的颗粒,从而使胶体金的比色信号得到放大,如专利CN102135536A。前两种方法由于需要对胶体金探针进行双标记,往往容易影响胶体金探针的免疫性能,导致方法学稳定性差。金或银染增强技术中金属纳米壳层的生长属于层层生长模式,其生长速率不仅与试纸条T、C线上金纳米粒子数量有关,而且与生长液的浓度以及生长时间密切相关,导致生长过程不可控,检测结果的稳定性和重现性差,大大限制了该方法在实践中的推广应用。此外这些方法提高检测灵敏度的能力是有限的,仅为1~2个数量级。因此增敏后的胶体金免疫层析试纸条依然无法实现低浓度待检物的超灵敏检测。本发明提出使用聚合物介导可控铜生长技术显著增强试纸条检测线上胶体金探针的光学信号强度,条带颜色呈现从无到有、从弱到强的变化,可实现超低目标物浓度下的裸眼定性检测。经检索未见有采用可控铜生长技术增敏传统胶体金免疫层析试纸条检测灵敏度的公开文献报道。The signal amplification strategy based on the test strip detection line has received extensive attention of researchers because it does not require the synthesis of additional auxiliary signal amplification materials. This type of strategy mainly includes the following categories: 1) Double gold signal amplification technology: On the basis of traditional colloidal gold immunochromatographic test strips, by introducing signal amplification gold label pads, it can use antigen-antibody reaction and biotin- Streptavidin system specifically binds gold-labeled antibody conjugates on the detection line, resulting in further aggregation of colloidal gold nanoparticles, thereby amplifying the colorimetric signal of colloidal gold, such as patent CN102507929A; 2) Enzyme enhancement technology: in On the basis of traditional colloidal gold immunochromatographic test strips, the introduction of horseradish peroxidase or nanozymes with peroxidase activity catalyzes the oxidation of corresponding substrates such as tetramethylbenzidine (TMB) to generate colored The precipitate is deposited on the detection line, so that the colorimetric signal of colloidal gold is amplified; 3) Gold or silver staining enhancement technology: On the basis of traditional colloidal gold immunochromatographic test strips, in the presence of a reducing agent, gold Or silver ions are easy to take colloidal gold as the core, gather on the surface of colloidal gold and reduce to gold or silver atoms, so that nano-sized colloidal gold grows into larger particles through the aggregation and reduction of gold or silver ions, so that the ratio of colloidal gold is reduced. The color signal is amplified, such as patent CN102135536A. The first two methods often easily affect the immunological properties of the colloidal gold probe due to the need for double labeling of the colloidal gold probe, resulting in poor methodological stability. The growth of metal nanoshells in the gold or silver staining enhancement technology belongs to the layer-by-layer growth mode. The growth rate is not only related to the number of gold nanoparticles on the T and C lines of the test strip, but also closely related to the concentration of the growth solution and the growth time. As a result, the growth process is uncontrollable, and the stability and reproducibility of the detection results are poor, which greatly limits the popularization and application of this method in practice. In addition, the ability of these methods to improve detection sensitivity is limited, only 1-2 orders of magnitude. Therefore, the sensitized colloidal gold immunochromatographic test strip still cannot realize the ultrasensitive detection of the low-concentration analyte. The invention proposes to use the polymer-mediated controllable copper growth technology to significantly enhance the optical signal intensity of the colloidal gold probe on the test strip detection line, and the color of the strip changes from zero to strong, from weak to strong, and can achieve ultra-low Qualitative detection with naked eye at target concentration. After searching, there is no published literature report on the use of controlled copper growth technology to sensitize the detection sensitivity of traditional colloidal gold immunochromatographic test strips.
发明内容SUMMARY OF THE INVENTION
本发明的目的是本发明旨在针对现有胶体金免疫层析试纸条因其20~40nm胶体金探针信号强度偏弱导致检测灵敏度偏低的现状缺陷,使用聚合物介导胶体金探针表面可控铜生长沉积显著放大试纸条检测线上胶体金探针的光学信号强度,提供了一种提高传统胶体金免疫层析方法检测灵敏度的新技术,实现对超低浓度目标检测物进行现场快速检测。The purpose of the present invention is that the present invention aims to solve the current defect of low detection sensitivity due to the weak signal intensity of the 20-40nm colloidal gold probe of the existing colloidal gold immunochromatographic test strip, using polymer-mediated colloidal gold probe The controllable copper growth deposition on the needle surface significantly amplifies the optical signal intensity of the colloidal gold probe on the test strip detection line, providing a new technology to improve the detection sensitivity of the traditional colloidal gold immunochromatography method, and realize the detection of ultra-low concentration target substances. Perform a quick on-site inspection.
为实现上述目的,本发明采用的技术方案是:For achieving the above object, the technical scheme adopted in the present invention is:
一种灵敏检新型冠状病毒抗体的增敏型免疫层析试剂盒,所述试剂盒包括胶体金免疫层析试纸条和铜生长液,胶体金免疫层析试纸条由样品垫、结合垫、硝酸纤维素膜、吸水纸依次固定于PVC塑料底板上,所述结合垫为喷涂有胶体金标记的新型冠状病毒(SARS-CoV-2)重组抗原和胶体金标记的兔IgG抗体的玻璃纤维膜,所述硝酸纤维素膜上设有检测线和质控线,检测线上包被有SARS-CoV-2重组抗原,质控线上包被有抗兔二抗溶液;所述铜生长液包括铜生长A液和铜生长B液,铜生长A液为聚合物和二价铜离子预先形成铜离子配位生长液,铜生长B液为抗坏血酸钠和柠檬酸三钠混合溶液。A sensitizing immunochromatographic kit for sensitive detection of novel coronavirus antibodies, the kit comprises a colloidal gold immunochromatographic test strip and a copper growth solution, and the colloidal gold immunochromatographic test strip consists of a sample pad, a binding pad , nitrocellulose membrane, and absorbent paper are sequentially fixed on the PVC plastic bottom plate, and the binding pad is a glass fiber sprayed with colloidal gold-labeled novel coronavirus (SARS-CoV-2) recombinant antigen and colloidal gold-labeled rabbit IgG antibody The nitrocellulose membrane is provided with a detection line and a quality control line, the detection line is coated with SARS-CoV-2 recombinant antigen, and the quality control line is coated with an anti-rabbit secondary antibody solution; the copper growth solution It includes copper growth solution A and copper growth solution B. Copper growth solution A is a pre-formed copper ion coordination growth solution formed by polymer and divalent copper ions. Copper growth solution B is a mixed solution of sodium ascorbate and trisodium citrate.
本发明还提供了一种灵敏检新型冠状病毒抗体的增敏型免疫层析试剂盒的制备方法,包括以下步骤:The present invention also provides a preparation method of a sensitized immunochromatographic kit for sensitive detection of novel coronavirus antibodies, comprising the following steps:
1)胶体金标记的重组抗原的制备:取1mL粒径为30~40nm柠檬酸包被胶体金溶液,用浓度0.2M的碳酸钾溶液调节该溶液的pH值至7.0~8.0;向溶液加入5μL浓度为1~2mg/mLSARS-CoV-2重组抗原溶液,室温下振荡反应30min;然后再将100μL1~2mg/mL牛血清白蛋白溶液加至上述混合溶液中继续于室温下振荡反应30min;在4℃条件下,于10000rpm离心20min,弃上清,沉淀物复溶于0.01M pH7.4磷酸盐缓冲溶液(PBS),得终产物胶体金标记的重组抗原;胶体金标记兔IgG抗体采用相同的方法完成,将SARS-CoV-2重组抗原溶液替换成兔IgG抗体溶液。1) Preparation of colloidal gold-labeled recombinant antigen: Take 1 mL of citric acid-coated colloidal gold solution with a particle size of 30-40 nm, adjust the pH of the solution to 7.0-8.0 with potassium carbonate solution with a concentration of 0.2 M; add 5 μL to the solution The concentration of SARS-CoV-2 recombinant antigen solution was 1~2mg/mL, and the reaction was shaken for 30min at room temperature; then 100 μL of 1~2mg/mL bovine serum albumin solution was added to the above mixed solution and the reaction was continued at room temperature for 30min; at 4 Under the condition of ℃, centrifuge at 10000rpm for 20min, discard the supernatant, and redissolve the precipitate in 0.01M pH7.4 phosphate buffer solution (PBS) to obtain the final product colloidal gold-labeled recombinant antigen; colloidal gold-labeled rabbit IgG antibody uses the same After the method was completed, the SARS-CoV-2 recombinant antigen solution was replaced with a rabbit IgG antibody solution.
2)胶体金免疫层析试纸条的制备:a)结合垫的制备是将胶体金标记的重组抗原和胶体金标记的兔IgG抗体喷涂于玻璃纤维膜上;b)具有检测线和质控线的硝酸纤维膜的制备是将浓度为1~2mg/mL SARS-CoV-2重组抗原和浓度为1~2mg/mL抗兔二抗溶液分别喷涂硝酸纤维膜上绘制两条线平行线,SARS-CoV-2重组抗原溶液划线作为检测线(T线),抗兔二抗溶液划线为质控线(C线);c)胶体金免疫层析试纸条组装:将样品垫、具有金标检测抗体的结合垫、具有T和C线的硝酸纤维膜和吸水纸分别依次粘贴到塑料衬板上,相邻重叠部分的长度为2mm,切割成4mm宽的试纸条,密封干燥,于温度保存;2) Preparation of colloidal gold immunochromatographic test strips: a) The preparation of the binding pad is to spray the colloidal gold-labeled recombinant antigen and colloidal gold-labeled rabbit IgG antibody on the glass fiber membrane; b) It has a detection line and a quality control The preparation of the nitrocellulose membrane of the line is by spraying the SARS-CoV-2 recombinant antigen with a concentration of 1-2 mg/mL and the anti-rabbit secondary antibody solution with a concentration of 1-2 mg/mL respectively on the nitrocellulose membrane to draw two parallel lines, SARS-CoV-2. - The CoV-2 recombinant antigen solution was streaked as the detection line (T line), and the anti-rabbit secondary antibody solution was streaked as the quality control line (C line); c) Colloidal gold immunochromatography test strip assembly: the sample pad, with The binding pad of the gold-labeled detection antibody, the nitrocellulose membrane with T and C lines, and the absorbent paper were respectively pasted onto the plastic backing plate in turn. stored at temperature;
3)铜生长液的配置:a)铜生长A液:准确称取200~400mg氯化铜和100~200mg聚合物分别溶解于10mL超纯水中,然后将二者混均制备得铜生长A液;b)铜生长B液:准确称取1~2g抗坏血酸钠和1mg柠檬酸三钠分别溶解于10mL和1mL超纯水中,然后将二者混均制备得铜生长B液。3) Configuration of copper growth solution: a) Copper growth solution A: Accurately weigh 200-400 mg of copper chloride and 100-200 mg of polymer and dissolve them in 10 mL of ultrapure water, respectively, and then mix the two to prepare copper growth A. b) Copper growth solution B: Accurately weigh 1-2 g of sodium ascorbate and 1 mg of trisodium citrate and dissolve them in 10 mL and 1 mL of ultrapure water, respectively, and then mix the two to prepare copper growth solution B.
进一步地,所述聚合物为聚乙烯亚胺PEI、聚丙烯酸PAA、聚乙烯吡咯烷酮PVP或聚赖氨酸PL。Further, the polymer is polyethyleneimine PEI, polyacrylic acid PAA, polyvinylpyrrolidone PVP or polylysine PL.
本发明还提供了一种灵敏检新型冠状病毒抗体的增敏型免疫层析试剂盒的使用方法,包括以下步骤:The present invention also provides a method for using a sensitized immunochromatographic kit for sensitive detection of novel coronavirus antibodies, comprising the following steps:
1)取100~120μL待测样品溶液加入到试纸条的检测卡加样孔中,于室温反应5~10min;1) Take 100-120 μL of the sample solution to be tested and add it to the sample hole of the test card of the test strip, and react at room temperature for 5-10 minutes;
2)将上述反应后的试纸条依次使用磷酸盐缓冲液和超纯水洗涤后,浸泡于铜生长A液中室温反应5min;2) after the above-reacted test strips were washed with phosphate buffer and ultrapure water in turn, soaked in copper growth A solution for reaction at room temperature for 5 min;
3)接着将试纸条转移至铜生长B液中继续反应2min,使聚合物介导铜纳米壳层可控生长沉积至胶体金表面,显著增强胶体金的光学信号强度,肉眼观察实验结果。3) Next, transfer the test strip to the copper growth solution B and continue to react for 2 minutes, so that the polymer-mediated copper nanoshell layer is controlled to grow and deposit on the surface of colloidal gold, which significantly enhances the optical signal intensity of colloidal gold, and the experimental results are observed with the naked eye.
本发明适用于疾病相关抗原及抗体标志物的超灵敏检测,所述的疾病相关标志物包括:肿瘤标志物如癌胚抗原、前列腺特异性抗原、甲胎蛋白;炎症标志物如C反应蛋白、降钙素原、白介素6;心肌标志物如肌钙蛋白、肌红蛋白、N末端心房利钠肽及N末端脑利钠肽;传染病标志物如新型冠状病毒抗原及抗体、艾滋病病毒抗原及抗体、埃博拉病毒抗原及抗体、中东呼吸综合征冠状病毒抗原及抗体、乙肝病毒相关抗原及抗体;病原体如病毒、致病菌等,特别是适合于待检物的现场快速超灵敏检测。样品处理按照常规处理方法即可。The invention is suitable for ultrasensitive detection of disease-related antigens and antibody markers, and the disease-related markers include: tumor markers such as carcinoembryonic antigen, prostate specific antigen, alpha-fetoprotein; inflammatory markers such as C-reactive protein, Procalcitonin, interleukin-6; cardiac markers such as troponin, myoglobin, N-terminal atrial natriuretic peptide and N-terminal brain natriuretic peptide; infectious disease markers such as novel coronavirus antigens and antibodies, HIV antigens and Antibodies, Ebola virus antigens and antibodies, Middle East respiratory syndrome coronavirus antigens and antibodies, hepatitis B virus-related antigens and antibodies; pathogens such as viruses, pathogenic bacteria, etc., especially suitable for on-site rapid ultrasensitive detection of objects to be tested. The sample processing can be carried out according to the conventional processing method.
与现有技术相比,本发明的有益效果是:Compared with the prior art, the beneficial effects of the present invention are:
1、本发明是在传统胶体金免疫层析试纸条的基础上,采用聚合物介导可控铜生长信号放大技术既提高了胶体金免疫层析试纸条的检测灵敏度,也保留了其特异性强的特点。1. On the basis of traditional colloidal gold immunochromatographic test strips, the present invention adopts polymer-mediated controllable copper growth signal amplification technology to improve the detection sensitivity of colloidal gold immunochromatographic test strips, and also retains its advantages. specific characteristics.
2、本发明所采用的聚合物介导可控铜生长信号放大技术涉及胶体金探针表面聚合物介导下抗坏血酸钠诱导二价铜离子的可控还原沉积。其原理为将完成常规检测后的胶体金试纸条依次浸泡于铜生长A液和B液,此时预吸附的铜离子被还原成铜单质沉积在胶体金探针表面并实现信号增强。该方案中被还原沉积在检测区域的铜纳米粒子数量与预吸附的铜离子数量有关,而预吸附的铜离子数量只与试纸条检测区域的胶体金探针数目有关,因而可实现铜纳米粒子可控生长。相较于传统的金银生长增敏型试纸条,该方法灵敏度更高、检测结果的准确性和可靠性更好。此外信号放大体系中所涉及的氯化铜、聚合物、抗坏血酸钠及柠檬酸三钠均已实现商业化大规模生产,因此本方法试剂成本低、稳定性高以及重现性好,具有较好的商业化前景。2. The polymer-mediated controllable copper growth signal amplification technology adopted in the present invention involves the controllable reduction deposition of divalent copper ions induced by sodium ascorbate under the mediation of polymers on the surface of colloidal gold probes. The principle is to immerse the colloidal gold test strip after the conventional detection in the copper growth liquid A and B in turn. At this time, the pre-adsorbed copper ions are reduced to copper and deposited on the surface of the colloidal gold probe to achieve signal enhancement. In this scheme, the number of copper nanoparticles reduced and deposited in the detection area is related to the number of pre-adsorbed copper ions, while the number of pre-adsorbed copper ions is only related to the number of colloidal gold probes in the detection area of the test strip. Controlled growth of particles. Compared with the traditional gold-silver growth-sensitizing test strips, the method has higher sensitivity and better accuracy and reliability of detection results. In addition, the copper chloride, polymer, sodium ascorbate and trisodium citrate involved in the signal amplification system have all achieved commercial large-scale production, so this method has low reagent cost, high stability and good reproducibility, and has good commercialization prospects.
3、本发明所使用聚合物介导可控铜生长信号放大技术可适用于所有胶体金免疫层析试纸条。3. The polymer-mediated controllable copper growth signal amplification technology used in the present invention can be applied to all colloidal gold immunochromatographic test strips.
4、本发明所构建的增敏型免疫层析试纸条特别适用于痕量目标分析物的超灵敏检测,在临床和突发事件的现场检测中具有广泛的应用前景,如传染病的早期筛查等。4. The sensitized immunochromatographic test strip constructed by the present invention is especially suitable for ultra-sensitive detection of trace target analytes, and has broad application prospects in clinical and on-site detection of emergencies, such as the early stage of infectious diseases. screening, etc.
附图说明Description of drawings
图1为试纸条结构示意图,为(A)是传统胶体金免疫层析试纸条结构图,(B)是本发明方法的原理示意图;Fig. 1 is a schematic diagram of a test strip structure, for (A) is a structure diagram of a traditional colloidal gold immunochromatographic test strip, and (B) is a schematic diagram of the principle of the method of the present invention;
图2为对新型冠状病毒感染者血清中抗体检测的示意图:传统胶体金免疫层析试纸条(上)和本发明所构建的增敏型试纸条(下)。Figure 2 is a schematic diagram of the detection of antibodies in the serum of patients with novel coronavirus infection: traditional colloidal gold immunochromatographic test strips (top) and sensitization test strips constructed by the present invention (bottom).
具体实施方式Detailed ways
以下将对本发明的具体实施方式进行详细描述。为了避免过多不必要的细节,在以下实施例中对属于公知的结构或功能将不进行详细描述。Specific embodiments of the present invention will be described in detail below. In order to avoid unnecessary details, well-known structures or functions will not be described in detail in the following embodiments.
除有定义外,以下实施例中所用的技术和科学术语具有与本发明所属领域技术人员普遍理解的相同含义。Unless defined otherwise, technical and scientific terms used in the following examples have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
以下实施例中所用的试验试剂耗材,如无特殊说明,均为常规生化试剂;所述实验方法,如无特殊说明,均为常规方法。The test reagent consumables used in the following examples are conventional biochemical reagents unless otherwise specified; the experimental methods are conventional methods unless otherwise specified.
在以下试验中,磷酸盐缓冲液(PBS,0.05M,pH 7.4)的配置方法如下:NaCl 40g,Na2HPO4 13.5g,KH2PO4 1.0g,KCl 1.0g溶于1L超纯水中。用0.1M NaOH调pH值至7.4。In the following experiments, phosphate buffered saline (PBS, 0.05M, pH 7.4) was prepared as follows: NaCl 40g, Na2HPO4 13.5g, KH2PO4 1.0g , KCl 1.0g dissolved in 1L ultrapure water . The pH was adjusted to 7.4 with 0.1M NaOH.
试验中所涉及的新型冠状病毒(SARS-CoV-2)重组抗原购于江西业力医疗器械有限公司。兔IgG抗体以及抗兔二抗均由北京热景生物技术股份有限公司提供。所述氯化铜、聚乙烯亚胺PEI、抗坏血酸钠及柠檬酸三钠均可自市面购得。The novel coronavirus (SARS-CoV-2) recombinant antigen involved in the test was purchased from Jiangxi Yeli Medical Equipment Co., Ltd. Rabbit IgG antibody and anti-rabbit secondary antibody were provided by Beijing Rejing Biotechnology Co., Ltd. The copper chloride, polyethyleneimine PEI, sodium ascorbate and trisodium citrate can be purchased from the market.
实施例1Example 1
一种用于增敏型胶体金免疫层析试纸条的检测试剂盒,它包括胶体金免疫层析试纸条和铜生长液;如图1中A所示,胶体金免疫层析试纸条包括样本垫、结合垫、NC膜和吸水纸,结合垫上设有用胶体金标记的新型冠状病毒重组抗原,硝酸纤维素膜上设有检测线(T线)和质控线(C线);铜生长液包括铜生长A液和B液。A detection kit for sensitizing colloidal gold immunochromatographic test strips, which includes colloidal gold immunochromatographic test strips and copper growth solution; as shown in A in Figure 1, the colloidal gold immunochromatographic test strips The strip includes a sample pad, binding pad, NC membrane and absorbent paper, the binding pad is provided with a novel coronavirus recombinant antigen labeled with colloidal gold, and the nitrocellulose membrane is provided with a detection line (T line) and a quality control line (C line); The copper growth solution includes copper growth A solution and B solution.
所述的试剂盒按以下方法制备得到:The kit was prepared as follows:
一、胶体金免疫层析试纸条的制备1. Preparation of colloidal gold immunochromatographic test strips
1、胶体金标记的重组抗原的制备:1. Preparation of colloidal gold-labeled recombinant antigen:
取1mL粒径为35nm柠檬酸包被胶体金溶液,用浓度0.2M的碳酸钾溶液调节该溶液的pH值至7.4;向溶液加入5μL浓度为1.5mg/mL新型冠状病毒(SARS-CoV-2)重组抗原溶液,室温下振荡反应30min;然后再将100μL 1.5mg/mL牛血清白蛋白溶液加至上述混合溶液中继续于室温下振荡反应30min;在4℃条件下,于10000rpm离心20min,弃上清,沉淀物复溶于0.01M pH7.4磷酸盐缓冲溶液(PBS),得终产物胶体金标记的重组抗原。胶体金标记兔IgG抗体采用类似方法完成。Take 1 mL of citric acid-coated colloidal gold solution with a particle size of 35 nm, and adjust the pH of the solution to 7.4 with potassium carbonate solution with a concentration of 0.2 M; ) reconstituted antigen solution, shake at room temperature for 30 minutes; then add 100 μL of 1.5 mg/mL bovine serum albumin solution to the above mixed solution and continue shaking at room temperature for 30 minutes; at 4°C, centrifuge at 10,000 rpm for 20 minutes, discard The supernatant and the precipitate were redissolved in 0.01M pH7.4 phosphate buffered solution (PBS) to obtain the final product colloidal gold-labeled recombinant antigen. Colloidal gold-labeled rabbit IgG antibodies were accomplished in a similar manner.
2、胶体金免疫层析试纸条的制备:2. Preparation of colloidal gold immunochromatographic test strips:
a)结合垫的制备是将胶体金标记的重组抗原和胶体金标记的兔IgG抗体喷涂于玻璃纤维膜上;a) The preparation of the binding pad is to spray the colloidal gold-labeled recombinant antigen and the colloidal gold-labeled rabbit IgG antibody on the glass fiber membrane;
b)具有检测线和质控线的硝酸纤维(NC)膜的制备是将浓度为1.5mg/mL SARS-CoV-2重组抗原和浓度为1.5mg/mL抗兔二抗溶液分别喷涂NC膜上绘制两条线平行线,SARS-CoV-2重组抗原溶液划线作为检测线(T线),抗兔二抗溶液划线为质控线(C线);b) The nitrocellulose (NC) membrane with detection line and quality control line was prepared by spraying 1.5 mg/mL SARS-CoV-2 recombinant antigen and 1.5 mg/mL anti-rabbit secondary antibody solution on the NC membrane respectively Draw two parallel lines, the SARS-CoV-2 recombinant antigen solution is drawn as the detection line (T line), and the anti-rabbit secondary antibody solution is drawn as the quality control line (C line);
c)胶体金免疫层析试纸条组装:将样品垫、具有金标检测抗体的结合垫、具有T和C线的NC膜和吸水纸分别依次粘贴到塑料衬板上,相邻重叠部分的长度为2mm,切割成4mm宽的试纸条,密封干燥,于温度保存。c) Assembly of colloidal gold immunochromatographic test strips: Paste the sample pad, the binding pad with gold-labeled detection antibody, the NC film with T and C lines, and the absorbent paper on the plastic backing plate in turn, and the adjacent overlapping parts The length is 2mm, cut into 4mm wide test strips, sealed and dried, and stored at temperature.
二、比色信号放大试剂的制备2. Preparation of colorimetric signal amplification reagents
3、铜生长液的配置:3. Configuration of copper growth solution:
a)铜生长A液:准确称取300mg氯化铜和150mg聚乙烯亚胺PEI分别溶解于10mL超纯水中,然后将二者混均制备A液;a) Copper growth liquid A: Accurately weigh 300 mg of copper chloride and 150 mg of polyethyleneimine PEI and dissolve them in 10 mL of ultrapure water, respectively, and then mix the two to prepare liquid A;
b)铜生长B液:准确称取1.5g抗坏血酸钠和1mg柠檬酸三钠分别溶解于10和1mL超纯水中,然后将二者混均制备B液。b) Copper growth liquid B: Accurately weigh 1.5 g of sodium ascorbate and 1 mg of trisodium citrate and dissolve them in 10 and 1 mL of ultrapure water, respectively, and then mix the two to prepare liquid B.
实施例2Example 2
应用实施例1所述的试剂盒执行本发明方法,用以验证该方法对新型冠状病毒(SARS-CoV-2)抗体的检测效果。The method of the present invention was performed by using the kit described in Example 1 to verify the detection effect of the method on antibodies against novel coronavirus (SARS-CoV-2).
参照图1中B所示流程,用移液器准确取120μL含不同浓度抗体的血清样品溶液加入到试纸条检测卡加样孔中,于室温反应10min;将上述反应后的试纸条依次使用磷酸盐缓冲液和超纯水洗涤后,浸泡于铜生长A液中室温反应5min;接着将试纸条转移至铜生长B液中继续反应2min,肉眼判读实验结果。Referring to the process shown in B in Figure 1, use a pipette to accurately take 120 μL of serum sample solutions containing different concentrations of antibodies, add them to the sample wells of the test strip detection card, and react at room temperature for 10 minutes; After washing with phosphate buffer and ultrapure water, soak them in copper growth solution A for 5 min at room temperature; then transfer the test strips to copper growth solution B and continue to react for 2 min, and interpret the experimental results with the naked eye.
如图2所示,当使用由江西业力医疗有限公司购买商业化胶体金试纸条检测10份由南昌大学第一附属医院收集的病人临床血清样本时,我们发现所有试纸条均只有质控线(C线)出现明显的红色条带,而检测线(T线)未见红色条带。然而执行本发明方法后,其中7份检测样本(编号:27、30、31、32、40、41、43)T线出现肉眼可见的红色条带,表明待测血清中含有新型冠状病毒抗体。As shown in Figure 2, when using commercial colloidal gold test strips purchased by Jiangxi Yeli Medical Co., Ltd. to test 10 clinical serum samples of patients collected by the First Affiliated Hospital of Nanchang University, we found that all test strips were only qualitative The control line (C line) has an obvious red band, but the detection line (T line) has no red band. However, after performing the method of the present invention, 7 of the test samples (numbers: 27, 30, 31, 32, 40, 41, 43) showed a red band visible to the naked eye on the T line, indicating that the serum to be tested contains novel coronavirus antibodies.
进一步与临床核酸检测结果进行比对分析显示上述7份血清样本所对应患者的核酸检测呈现阳性结果,表明本发明所建立的方法具有更高的检测灵敏度,能够检测出传统胶体金免疫层析试纸条未能成功检测的“假阴性”样本,有效地避免了漏检。此外,3份临床核酸确证阴性的血清样本(编号:17、60、61)放大后其T线未见肉眼可见的条带,表明该放大方法具有良好的特异性。Further comparison and analysis with the clinical nucleic acid detection results showed that the nucleic acid detection of the patients corresponding to the above 7 serum samples showed positive results, indicating that the method established by the present invention has higher detection sensitivity and can detect the traditional colloidal gold immunochromatographic test. The "false negative" samples that were not successfully detected by the note effectively avoided the missed detection. In addition, 3 serum samples with negative clinical nucleic acid confirmation (No. 17, 60, 61) showed no visible bands on their T lines after amplification, indicating that the amplification method has good specificity.
结论:经实施例2所述的检测试验发现,本发明中所提到的新方法对临床新型冠状病毒感染者血清样本中抗体检测较传统胶体金免疫层析试纸条具有更高的检测灵敏度,更适合用于临床血清样本中痕量抗体的超灵敏检测,进一步证明本发明所提供的基于聚合物介导可控铜生长技术增敏传统胶体金免疫层析试纸条的新方法是可行的。Conclusion: The detection test described in Example 2 shows that the new method mentioned in the present invention has higher detection sensitivity than traditional colloidal gold immunochromatographic test strips for antibody detection in serum samples of clinical patients with novel coronavirus infection , more suitable for ultra-sensitive detection of trace antibodies in clinical serum samples, further proves that the new method of sensitizing traditional colloidal gold immunochromatographic test strips based on polymer-mediated controllable copper growth technology provided by the present invention is feasible of.
尽管本发明以新型冠状病毒(SARS-CoV-2)抗体作为模式分析物在双抗原夹心免疫层析平台上探讨聚合物介导可控铜生长技术增强免疫层析试纸条检测灵敏度的可行性,但是本发明所限定的内容并不局限于新型冠状病毒(SARS-CoV-2)抗体,其他所有使用本发明方法检测其他的目标分析物如生物大分子、核酸以及病原体等均在本专利的保护范围之内。此外,除了使用传统抗原抗体反应,本发明还可以采用近些年出现的新型生物识别反应如核酸杂交、核酸适配体、配受体等构建相应超灵敏的分析方法用于目标分析物的检测。因此,基于这些识别分子对本发明的拓展和延伸也在本发明所保护的范围之内。Although the present invention uses novel coronavirus (SARS-CoV-2) antibody as a model analyte to explore the feasibility of polymer-mediated controllable copper growth technology to enhance the detection sensitivity of immunochromatographic test strips on a double-antigen sandwich immunochromatography platform , but the content defined by the present invention is not limited to the new coronavirus (SARS-CoV-2) antibody, and all other target analytes such as biological macromolecules, nucleic acids and pathogens detected by the method of the present invention are included in the patent. within the scope of protection. In addition, in addition to using traditional antigen-antibody reactions, the present invention can also use new biological recognition reactions that have appeared in recent years, such as nucleic acid hybridization, nucleic acid aptamers, ligand receptors, etc. to construct corresponding ultra-sensitive analysis methods for the detection of target analytes . Therefore, the development and extension of the present invention based on these recognition molecules also fall within the protection scope of the present invention.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010310112.2A CN111505281A (en) | 2020-04-17 | 2020-04-17 | A sensitizing immunochromatographic kit for sensitive detection of novel coronavirus antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010310112.2A CN111505281A (en) | 2020-04-17 | 2020-04-17 | A sensitizing immunochromatographic kit for sensitive detection of novel coronavirus antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111505281A true CN111505281A (en) | 2020-08-07 |
Family
ID=71869605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010310112.2A Pending CN111505281A (en) | 2020-04-17 | 2020-04-17 | A sensitizing immunochromatographic kit for sensitive detection of novel coronavirus antibodies |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111505281A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111650370A (en) * | 2020-08-10 | 2020-09-11 | 苏州微湃医疗科技有限公司 | Detection method and detection device of novel coronavirus SARS-CoV-2 |
CN112098656A (en) * | 2020-08-25 | 2020-12-18 | 广州优迪生物科技股份有限公司 | HRP immunochromatographic reagent strip for detecting human SARS-CoV-2 and preparation method thereof |
CN113189329A (en) * | 2020-10-14 | 2021-07-30 | 北京化工大学 | Multiple immunity colorimetric virus detection method based on monatomic nanoenzyme |
CN113244916A (en) * | 2021-05-13 | 2021-08-13 | 国家纳米科学中心 | Nano enzyme and application thereof |
CN113466449A (en) * | 2021-05-14 | 2021-10-01 | 南昌大学 | Gold magnetic nano immunoassay kit for high-sensitivity multi-element field detection and manufacturing method and detection method thereof |
CN114062673A (en) * | 2021-11-23 | 2022-02-18 | 济南百博生物技术股份有限公司 | High-sensitivity neocorona antigen detection reagent strip and preparation method thereof |
WO2022040523A1 (en) * | 2020-08-20 | 2022-02-24 | BiopolariX Scientific, LLC | Saliva testing kit using nano carbon immunochromatography |
CN114636817A (en) * | 2022-02-08 | 2022-06-17 | 广东环凯生物科技有限公司 | Kit and method for detecting escherichia coli O157H 7 based on polyacrylamide hydrochloride mediated copper growth enhancement |
CN115575632A (en) * | 2022-12-07 | 2023-01-06 | 广州国家实验室 | Detection test strip and application |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100230644A1 (en) * | 2007-11-05 | 2010-09-16 | Kazuomi Ryoshi | Copper fine particles, method for producing the same, and copper fine particle dispersion |
JP2011209069A (en) * | 2010-03-29 | 2011-10-20 | Institute Of National Colleges Of Technology Japan | High sensitivity immunoassay |
CN103063844A (en) * | 2012-10-30 | 2013-04-24 | 东南大学 | Immune chromatography test paper detection method based on catalyzing and amplifying of detection signal |
CN104181298A (en) * | 2014-09-02 | 2014-12-03 | 秦志浩 | Human parainfluenza virus (HPIVs) IgM antibody detection test strip and preparation method thereof |
CN107860920A (en) * | 2017-11-01 | 2018-03-30 | 杭州微瑞科技有限公司 | Rabies virus antibodies Quantitative detection card and application method |
CN208224282U (en) * | 2017-11-01 | 2018-12-11 | 杭州微瑞科技有限公司 | Canine coronavirus antibody quantifies rapid detection system |
CN109342715A (en) * | 2018-10-09 | 2019-02-15 | 浙江度安生物科技有限公司 | A kind of enhanced sensitivity reagent enhancing colloid gold chromatographic test paper signal strength and the photosensitivity-enhancing method using enhanced sensitivity reagent |
CN110770572A (en) * | 2017-02-09 | 2020-02-07 | Essenlix公司 | Colorimetric assay |
-
2020
- 2020-04-17 CN CN202010310112.2A patent/CN111505281A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100230644A1 (en) * | 2007-11-05 | 2010-09-16 | Kazuomi Ryoshi | Copper fine particles, method for producing the same, and copper fine particle dispersion |
JP2011209069A (en) * | 2010-03-29 | 2011-10-20 | Institute Of National Colleges Of Technology Japan | High sensitivity immunoassay |
CN103063844A (en) * | 2012-10-30 | 2013-04-24 | 东南大学 | Immune chromatography test paper detection method based on catalyzing and amplifying of detection signal |
CN104181298A (en) * | 2014-09-02 | 2014-12-03 | 秦志浩 | Human parainfluenza virus (HPIVs) IgM antibody detection test strip and preparation method thereof |
CN110770572A (en) * | 2017-02-09 | 2020-02-07 | Essenlix公司 | Colorimetric assay |
CN107860920A (en) * | 2017-11-01 | 2018-03-30 | 杭州微瑞科技有限公司 | Rabies virus antibodies Quantitative detection card and application method |
CN208224282U (en) * | 2017-11-01 | 2018-12-11 | 杭州微瑞科技有限公司 | Canine coronavirus antibody quantifies rapid detection system |
CN109342715A (en) * | 2018-10-09 | 2019-02-15 | 浙江度安生物科技有限公司 | A kind of enhanced sensitivity reagent enhancing colloid gold chromatographic test paper signal strength and the photosensitivity-enhancing method using enhanced sensitivity reagent |
Non-Patent Citations (2)
Title |
---|
同重湘 等: "基于金标免疫层析技术SARS-CoV-2抗体检测COVID-19的临床应用价值分析", 《兰州大学学报(医学版)》 * |
周耀锋: "两种提高传统免疫学分析方法检测灵敏度的新型信号放大策略研究", 《万方数据 硕士论文》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111650370A (en) * | 2020-08-10 | 2020-09-11 | 苏州微湃医疗科技有限公司 | Detection method and detection device of novel coronavirus SARS-CoV-2 |
WO2022040523A1 (en) * | 2020-08-20 | 2022-02-24 | BiopolariX Scientific, LLC | Saliva testing kit using nano carbon immunochromatography |
CN112098656A (en) * | 2020-08-25 | 2020-12-18 | 广州优迪生物科技股份有限公司 | HRP immunochromatographic reagent strip for detecting human SARS-CoV-2 and preparation method thereof |
CN113189329A (en) * | 2020-10-14 | 2021-07-30 | 北京化工大学 | Multiple immunity colorimetric virus detection method based on monatomic nanoenzyme |
CN113244916A (en) * | 2021-05-13 | 2021-08-13 | 国家纳米科学中心 | Nano enzyme and application thereof |
CN113466449A (en) * | 2021-05-14 | 2021-10-01 | 南昌大学 | Gold magnetic nano immunoassay kit for high-sensitivity multi-element field detection and manufacturing method and detection method thereof |
CN114062673A (en) * | 2021-11-23 | 2022-02-18 | 济南百博生物技术股份有限公司 | High-sensitivity neocorona antigen detection reagent strip and preparation method thereof |
CN114636817A (en) * | 2022-02-08 | 2022-06-17 | 广东环凯生物科技有限公司 | Kit and method for detecting escherichia coli O157H 7 based on polyacrylamide hydrochloride mediated copper growth enhancement |
CN114636817B (en) * | 2022-02-08 | 2022-12-13 | 广东环凯生物科技有限公司 | Kit and method for detecting escherichia coli O157H 7 based on polyacrylamide hydrochloride mediated copper growth enhancement |
CN115575632A (en) * | 2022-12-07 | 2023-01-06 | 广州国家实验室 | Detection test strip and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111505281A (en) | A sensitizing immunochromatographic kit for sensitive detection of novel coronavirus antibodies | |
CN104655836B (en) | Immunochromatographic test strip, detection method by using immunochromatographic test strip, and application of immunochromatographic test strip | |
CN108459159B (en) | Novel method for enhancing sensitivity of immunochromatographic test strip by using supermolecular self-assembly mediated reticular nanogold | |
CN102778561B (en) | Preparation and application of tumor marker immunosensor built by putamen nanometer materials | |
Tian et al. | Copper deposition-induced efficient signal amplification for ultrasensitive lateral flow immunoassay | |
CN102507929B (en) | Preparation method of signal-enhancement type immunochromatographic gold-labeled test strip | |
CN112964763B (en) | Electroactive material modified MOF composite electrochemical immunosensor and its preparation and application | |
CN102967706A (en) | Preparation method and application of flow injection chemiluminiscence immuno sensor for detecting tumor marker | |
CN112415193A (en) | Novel method for quickly detecting magnetic bimetallic nanoenzyme based on polydopamine mediation | |
CN100504390C (en) | Color latex chromatography diagnostic test strip and its preparation method | |
WO2015119386A1 (en) | High-sensitivity and lateral-flow immunochromatographic chip using enzyme-mimic inorganic nanoparticles and detection method using same | |
CN115060888A (en) | A kind of preparation method of novel coronavirus nucleocapsid protein antigen detection test paper | |
Xu et al. | A highly sensitive electrochemiluminescence immunosensor based on magnetic nanoparticles and its application in CA125 determination | |
CN115267185A (en) | Helicobacter pylori antigen colloidal gold detection reagent strip | |
Ge et al. | Ultra-sensitive magnetic immunoassay of HE4 based on surface enhanced Raman spectroscopy | |
JP5104622B2 (en) | Method for measuring the concentration of analytes using magnetic particles | |
CN111505280A (en) | A colloidal gold immunochromatographic kit for ultrasensitive detection of Listeria monocytogenes | |
CN110231489A (en) | A method of improving the test strip biosensor detection sensitivity of carbon nanotube label | |
CN102253194A (en) | Secondary antibody probe for sandwich immune reaction by using amperometric immunosensor | |
Yang et al. | Au/Fe 3 O 4-based nanozymes with peroxidase-like activity integrated in immunochromatographic strips for highly-sensitive biomarker detection | |
CN113325179A (en) | Immunochromatographic test strip based on Au @ Pt enzyme and preparation method thereof | |
CN111693689B (en) | Nanoenzyme for enzymatic chemiluminescence detection and application thereof | |
CN113109558A (en) | Magnetic particle chemiluminescence kit for quantitatively detecting CYFRA21-1 and manufacturing method thereof | |
CN111505279B (en) | Method for silver growth enhanced ultrasensitive detection of rotavirus | |
CN115598339B (en) | Gold nano composite particle capable of detecting heavy metal ions and immunochromatography test strip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200807 |